Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 12/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.49 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.47 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2895511 | 0.81 | MCHR1 (0.68) | MCHR1KCNH2HRH3 | |
| SCHEMBL2890458 | 0.80 | MCHR1 (0.68) | MCHR1KCNH2HRH3 | |
| SCHEMBL1000731 | 0.77 | MCHR1 (0.82) | MCHR1KCNH2HRH3 | |
| SCHEMBL1364747 | 0.77 | MCHR1 (0.63) | MCHR1HRH3MBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL13649141 | 0.75 | HRH3 (0.68) | HRH3MBTD1L3MBTL3L3MBTL1SLC6A3 | |
| SCHEMBL14100544 | 0.73 | HRH3 (0.71) | HRH3MBTD1L3MBTL3L3MBTL1SLC6A3 | |
| SCHEMBL4689587 | 0.73 | HRH3 (0.71) | HRH3MBTD1L3MBTL3L3MBTL1SLC6A3 | |
| SCHEMBL1002897 | 0.72 | MCHR1 (0.64) | MCHR1KCNH2HRH3 | |
| SCHEMBL539185 | 0.72 | MCHR1 (0.70) | MCHR1KCNH2 | |
| SCHEMBL20747933 | 0.71 | HRH3 (0.62) | HRH3MBTD1L3MBTL3L3MBTL1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875633-B2 | 4-[(4-Chlorobenzyl)oxy]-1-(4-[(1E)-3-(methylamino)-1-propen-1-yl]phenyl)pyridin-2(1H)-one; remedy for metabolic disorders such as obesity, diabetes, hormone disorder; cardiovascular disorders (stenocardia, acute or congestive heart failure); nervous system disorders (bulimia, anxiety, epilepsy etc.) | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-01-25 | — | — | US | disclosed |
| EP-1921065-B1 | PHENYLPYRIDONE DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20090137587-A1 | Phenylpyridone Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1921065-A1 | PHENYLPYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137587-A1 | Phenylpyridone Derivative | NAT1, NPR1, PC | MCHR1 439/4885KCNH2 781/4885HRH3 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.